Bristol Myers Squibb launches heart medication Kopozgo in Indian market

Bristol Myers Squibb Launches Heart Drug “Kopozgo” in India

Context

Global biopharmaceutical firm Bristol Myers Squibb (BMS) has launched Kopozgo (Mavacamten) — a breakthrough oral cardiac drug — in the Indian market.

About the Drug

• Name: Kopozgo (Mavacamten)
• Type: Oral, selective cardiac myosin inhibitor
• Use: Treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults.
• Regulatory Approval:
  • Approved by Central Drugs Standard Control Organisation (CDSCO)
  • Import license issued: March 6, 2025

Clinical Background

Approval is based on positive efficacy and safety data from two Phase III clinical trials:

• EXPLORER-HCM
• VALOR-HCM

Significance

• First and only oral therapy of its kind approved in India.
• Addresses a major unmet need in cardiovascular treatment.
• Strengthens India’s access to advanced cardiac care solutions.
  
  Updated : Oct 15 2025 | 11:45 PM | Business Standard